Pfizer reorg came on heels of its walk-back on price hikes
Pfizer announced on Wednesday its intent to reorganize into three businesses from two and will now include discrete units for science-based innovative medicines, consumer healthcare, and off-patent branded and generic established medicines.
More streamlined experience
Pfizer is well-known for its habit of restructuring, though analysts hailed this one as different owing to the imminent expiration of several patents.
The Financial Times first reported last week that Pfizer would continue its biannual price increases on many of its most popular drugs, including erectile dysfunction drug Viagra and Lyrica.